Panacea finds no cure-all for its financial woes
This article was originally published in Scrip
Executive Summary
Panacea Biotec, India's second largest vaccine producer, finds itself in an unenviable financial position with substantial net worth erosion, highlighting what some experts say are the perils of dependence on "binary" tender-based bulk purchases.
You may also be interested in...
Indian Panel Revises Bharat Vaccine Approval Amid 'Objections'
Bharat Biotech's quadrivalent (DPT-Hib) vaccine will have to go through Phase III trials after rival Panacea Biotec questions India's market authorization of the product.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.